|
|
Volumn 164, Issue 8, 2007, Pages 1266-
|
|
Pretrial medication bias in randomized antipsychotic drug trials [1]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ATYPICAL ANTIPSYCHOTIC AGENT;
HALOPERIDOL;
NEUROLEPTIC AGENT;
PERPHENAZINE;
QUETIAPINE;
RISPERIDONE;
CLINICAL FEATURE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
DISEASE EXACERBATION;
DRUG EFFICACY;
DRUG WITHDRAWAL;
HUMAN;
LETTER;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
RECEPTOR BINDING;
SCHIZOPHRENIA;
STRATIFICATION;
TREATMENT OUTCOME;
TREATMENT RESPONSE;
ANTIPSYCHOTIC AGENTS;
BIAS (EPIDEMIOLOGY);
DRUG ADMINISTRATION SCHEDULE;
HALOPERIDOL;
HUMANS;
RANDOMIZED CONTROLLED TRIALS;
RESEARCH DESIGN;
RISPERIDONE;
SCHIZOPHRENIA;
SCHIZOPHRENIC PSYCHOLOGY;
SEVERITY OF ILLNESS INDEX;
TREATMENT OUTCOME;
|
|
EID: 34548084050
PISSN: 0002953X
EISSN: None
Source Type: Journal
DOI: 10.1176/appi.ajp.2007.07030404 Document Type: Letter |
|
Times cited : (2)
|
|
References (3)
|
